These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27860290)

  • 1. Predictive glycoengineering of biosimilars using a Markov chain glycosylation model.
    Spahn PN; Hansen AH; Kol S; Voldborg BG; Lewis NE
    Biotechnol J; 2017 Feb; 12(2):. PubMed ID: 27860290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Markov chain model for N-linked protein glycosylation--towards a low-parameter tool for model-driven glycoengineering.
    Spahn PN; Hansen AH; Hansen HG; Arnsdorf J; Kildegaard HF; Lewis NE
    Metab Eng; 2016 Jan; 33():52-66. PubMed ID: 26537759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar.
    Rameez S; Gowtham YK; Nayar G; Mostafa SS
    Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coupling CRISPR interference with FACS enrichment: New approach in glycoengineering of CHO cell lines for therapeutic glycoprotein production.
    Glinšek K; Kramer L; Krajnc A; Kranjc E; Pirher N; Marušič J; Hellmann L; Podobnik B; Štrukelj B; Ausländer D; Gaber R
    Biotechnol J; 2022 Jul; 17(7):e2100499. PubMed ID: 35481906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.
    Borza B; Szigeti M; Szekrenyes A; Hajba L; Guttman A
    J Pharm Biomed Anal; 2018 May; 153():182-185. PubMed ID: 29499461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering.
    Liang C; Chiang AWT; Hansen AH; Arnsdorf J; Schoffelen S; Sorrentino JT; Kellman BP; Bao B; Voldborg BG; Lewis NE
    Curr Res Biotechnol; 2020 Nov; 2():22-36. PubMed ID: 32285041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
    MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality.
    Brühlmann D; Sokolov M; Butté A; Sauer M; Hemberger J; Souquet J; Broly H; Jordan M
    Biotechnol Bioeng; 2017 Jul; 114(7):1448-1458. PubMed ID: 28197999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive approach for evaluating charge heterogeneity in biosimilars.
    Xiao Z; Yin X; Han L; Sun B; Shen Z; Liu W; Yu F
    Eur J Pharm Sci; 2018 Mar; 115():19-24. PubMed ID: 29325754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders.
    Grampp G; Ramanan S
    BioDrugs; 2015 Dec; 29(6):365-72. PubMed ID: 26581551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the glycosylation aspects of biosimilarity.
    Hajba L; Szekrényes Á; Borza B; Guttman A
    Drug Discov Today; 2018 Mar; 23(3):616-625. PubMed ID: 29337201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Need for a risk-based control strategy for managing glycosylation profile for biosimilar products.
    Rathore A; Malani H
    Expert Opin Biol Ther; 2022 Feb; 22(2):123-131. PubMed ID: 34431439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
    Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
    J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying the differences in mechanisms of mycophenolic acid controlling fucose content of glycoproteins expressed in different CHO cell lines.
    Zhang A; Tsang VL; Markely LR; Kurt L; Huang YM; Prajapati S; Kshirsagar R
    Biotechnol Bioeng; 2016 Nov; 113(11):2367-76. PubMed ID: 27093551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of glycoprofiles of rituximab versions licensed for sale in India and an analytical approach for quality assessment.
    Kaur T; Shukla BN; Yadav VK; Kulkarni MJ; Rao A
    J Proteomics; 2021 Jul; 244():104267. PubMed ID: 34015520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress.
    Gupta T; Seshadri S
    Bioprocess Biosyst Eng; 2024 Jan; 47(1):57-64. PubMed ID: 38156991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global RNA-seq-driven analysis of CHO host and production cell lines reveals distinct differential expression patterns of genes contributing to recombinant antibody glycosylation.
    Könitzer JD; Müller MM; Leparc G; Pauers M; Bechmann J; Schulz P; Schaub J; Enenkel B; Hildebrandt T; Hampel M; Tolstrup AB
    Biotechnol J; 2015 Sep; 10(9):1412-23. PubMed ID: 26212696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.